A Phase I/II Dose Escalation study of the tumor-targeting L19-IL2 antibody-cytokine in combination with Dacarbazine for patients with metastatic melanoma

Mise à jour : Il y a 4 ans
Référence : EUCTR2012-004495-19

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

Phase I: Maximum tolerated dose (MTD) and the recommended dose (RD) of L19IL2 for phase II when administered in combination with a fixed dose of DTIC. Phase II: Antitumor activity in terms of best objective response rate (BORR) in patients treated with L19-IL2 at RD in combination with DTIC versus patients treated with DTIC monotherapy.


Critère d'inclusion

  • Metastatic Melanoma stage IV

Liens